Shikonin and its derivatives: A patent review

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 9, 2012, Pages 977-997

  Wang, Rubing ^a   Yin, Runting ^b   Zhou, Wen ^a   Xu, Defeng ^a   Li, Shaoshun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

Author keywords

Anticancer; Cytotoxicity; Mechanism; Reactive oxygen species; Shikonin; Shikonin derivatives; Total synthesis

Indexed keywords

(DEXTRO) SHIKONIN; 5,8 DIACETOXYL 6(1' ACETOXYL 4' METHYL 3' PENTENYL) 1,4 NAPHTHAQUINONE; ACETYL SHIKONIN; ALKANIN; ALPHA METHYL N BUTYRYLSHIKONIN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARNEBIN 5; ARNEBINONE; BETA ACETOXYISOVALERYL SHIKONIN; BETA BETA DIMETHYLACRYLSHIKONIN; BETA HYDROXYISOVALERYL SHIKSONIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOBUTYRYLSHIKONIN; ISOVALERYLSHIKONIN; LITHOSPERMIDIN A; LITHOSPERMIDIN B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEIN BAX; PROTEIN BCL XL; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SHIKONIN; SHIKONIN DERIVATIVE; SHIKONIN GLUCOSAMINOSIDE; TERACRYL SHIKONIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CELL DEATH; CHRONIC ARTHRITIS; CLINICAL EFFECTIVENESS; CYTOTOXICITY; DIABETES MELLITUS; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; NONHUMAN; PAW EDEMA; REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DESIGN; HUMANS; LITHOSPERMUM; NAPHTHOQUINONES; NEOPLASMS; PATENTS AS TOPIC; PLANT EXTRACTS;

EID: 84865528891     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.709237     Document Type: Review

References (102)

1. Papageorgiou VP, Assimopoulou AN, Couladouros EA, et al. The chemistry and biology of alkannin, shikonin, and related naphthazarin natural products. Angew Chem Int Ed 1999;38:270-300. A powerful review on shikonin compounds in 1999. (Pubitemid 29090823)
2. Papageorgiou VP. Naturally occurring isohexenylnaphthazarin pigments: A new class of drugs. Planta Med 1980;38:193-203 (Pubitemid 10065821)
3. Tanaka S, Tajima M. A comparative study on anti-inflammatory activities of the enantiomers, shikonin and alkannin. J Nat Prod 1986;49:466-9 (Pubitemid 16045809)
4. Chen X, Yang L, Oppenheim J, et al. Cellular pharmacology studies of shikonin derivatives. Phytother Res 2002;16:199-209 (Pubitemid 34534943)
5. Hayashi M. Effect of topical application of the ether extracts and shiunko on inflammatory reactions. Nippon Yakurigaku Zasshi 1977;73:205-14
6. Wagner H, Kreher B, Jurcic K. In vitro stimulation of human granulocytes and lymphocytes by pico- and femtogram quantities of cytostastic agents. Arzneim Forsch Drug Res 1988;38:273-5 (Pubitemid 18045094)
7. Hisa T, Kimura Y, Takada K, et al. Shikonin, an ingredient of lithospermum erythrorhizon, inhibits angiogenesis in vivo and in vitro. Anticaner Res 1998;18:783-90 (Pubitemid 28239595)
8. Ordoudi AS, Tsermentseli SK, Nenadis N, et al. Structure-radical scavenging activity relationship of alkannin/shikonin derivatives. Food Chem 2011;124:171-6
9. Chang YS, Kuo SC, Weng SH, et al. Inhibition of platelet aggregation by shikonin derivatives isolated from arnebia euchroma. Planta Med 1993;59:401-3
10. Wang R, Zhou S, Jiang HDGL, et al. An efficient multigram synthesis of alkannin and shikonin. Eur J Org Chem 2012;2012:1373-9. The first and most practical approach to obtain shikonin and its derivatives by chemical resolution.
11. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-7
12. Ahn BZ, Baik KU, Kweon GR. Acylshikonin analogs: Synthesis and inhibition of DNA topoisomerase-I. J Med Chem 1995;38:1044-7
13. Zhou W, Peng Y, Li S. Semi-synthesis and anti-tumor activity of 5,8-Odimethyl acylshikonin derivatives. Eur J Med Chem 2010;45:6005-11
14. Rao Z, Liu X, Zhou W, et al. Synthesis and antitumour activity of beta-hydroxyisovaleryl shikonin analogues. Eur J Med Chem 2011;46:3934-41
15. Zhou W, Zhang X, Xiao L, et al. Semi-synthesis and antitumor activity of 6- isomers of 5,8-O-dimethyl acylshikonin derivatives. Eur J Med Chem 2011;46:3420-7. The modifications on the mother nucleus of shikonin to obtain related derivatives with higher selectivity and lower toxicity.
16. Wang R, Zhou S, Li S. Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr Med Chem 2011;18:3168-89
17. Sevimli-Gur S, Akgun IH, Deliloglu-Gurhan I, et al. Cytotoxic naphthoquinones from alkanna cappadocica. J Nat Prod 2010;73:860-4
18. Wang RB, Zheng XG, Zhou W, et al. An efficient synthesis of 1,4,5,8- tetrameth- oxy-2-naphthaldehyde. J Chem Res 2010;34:520-1
19. Terada A, Tanoue Y, Hatada A, et al. Total synthesis of shikalkin. J Chem Soc Chem Commun 1983;1983:987-8
20. Tanoue Y, Terada A, Sugyo Y. Cycloshikonin and its derivatives. A synthetic route of shikonin. J Org Chem 1987;52:1437-9
21. Moiseenkov AM, Balaneva NN, Novikov VL, et al. Total synthesis of shikalkin. Dokl Akad Nauk SSSR 1987;295:614-17
22. Novikov VL, Balaneva NN, Moiseenkov AM, et al. Synthesis of shikalkin and certain related compounds. Bull Russ Acad Sci Div Chem Sci 1992;41:1485-92
23. Torii S, Akiyama K, Yamashita H, et al. Synthesis of dl-shikonin by vanadium (II)-assisted cross-coupling and electrooxidation of aromatic nuclei. Bull Chem Soc Jpn 1995;68:2917-22
24. Lu Q, Duan W, Cai J. A simple synthesis of dl-shikonin. Chinese Chem Lett 2002;13:113-14
25. Zhao LM, Xu DF, Zhou W, et al. Concise formal synthesis of (±)-shikonin via a highly alpha-regioselective prenylation of 1, 4, 5,8 - tetramethoxynaphthalene -2- carbaldehyde. Lett Org Chem 2008;5:234-6
26. Zhao LM, Jin HS, Wan LJ, et al. General and highly alpha-regioselective zinc- mediated prenylation of aldehydes and ketones. J Org Chem 2011;76:1831-7
27. Li SS, Xu DF. Total synthesis of racemic shikonin. CN100336792; 2007
28. Shimai Y, Koga T. Preparation of shikonin. JP63156741; 1988
29. Nicolaou KC, Hepworth D. Concise and efficient total syntheses of alkannin and shikonin. Angew Chem Int Edit 1998;37:839-41. The shortest synthesis of shikonin. (Pubitemid 28214100)
30. Rao Z, Zhou W, Peng Y, et al. An efficient improvement on total synthesis of shikonin. J Chem Res 2010;11:237-8
31. Couladouros EA, Strongilos AT, Papageorgiou VP, et al. A new efficient route for multigram asymmetric synthesis of alkannin and shikonin. Chem Eur J 2002;8:1795-803 (Pubitemid 34438312)
32. Wang R, Guo H, Cui JH, et al. A novel and efficient total synthesis of shikonin. Tetrahedron Lett 2012;53:3977-80
33. Li SS, Wang RB. Method for preparation of high-optical purity shikonin via asymmetric synthesis. CN102199080; 2011
34. Zhang WB, Xie F, Liu DL, et al. Ruthenocene diphosphine ligand with C2 symmetry and sole planar chirality. WO2007140717; 2007
35. Li SS, Wang RB. Method for preparation of high optical purity shikonin, alkannin and their derivatives. CN102399139; 2012
36. He H, Bai LP, Jiang ZH. Synthesis and human telomeric G-quadruplex DNA - binding activity of glucosaminosides of shikonin/alkannin. Bioorg Med Chem Lett 2012;22:1582-6
37. Papageorgiou VP, Assimopoulou AN, Ballis AC. Alkannins and shikonins: A new class of wound healing agents. Curr Med Chem 2008;15:3248-67
38. Papageorgiou VP, Assimopoulou AN, Samanidou VF. Analytical methods for the determination of alkannins and shikonins. Curr Org Chem 2006;10:583-622
39. Ito Y, Onobori K, Yamazaki T, et al. Tigloylshikonin, a new minor shikonin derivative, from the roots and the commercial root extract of lithospermum erythrorhizon. Chem Pharm Bull 2011;59:117-19
40. Wang YG, Su YH, Xie JS, et al. Preparation of saccharide acetate derivatives of shikonin as antitumor agents. CN101671376; 2010
41. Yang YH, Wang XM, Liu SH, et al. Preparation of saccharide derivative of shikonin as antitumor agents. CN101392010; 2011
42. Wang YG, Su YH, Xie JS, et al. Simple method for synthesis of shikonin carbamate derivative and its medical application. CN101671278; 2010
43. Li SS, Rao Z, Yi J, et al. Method for preparation of beta- hydroxyisovalerylalkannin derivatives and medical application as antitumor agent. CN101863766; 2010
44. Li SS, Zhou W, Xu DF, et al. Method for synthesis of alkannin dimethyl ether derivatives. CN101139287; 2010
45. Li SS, Zhou W, Xu DF, et al. Alkannin dimethyl ether with 6-side chain isomer, and its derivative and synthetic method. CN101182290; 2010
46. Zeng JZ, Zhang XK, Liu J, et al. Use of shikonin derivatives extracted from lithospermum erythrorhizon as anticancer agent for treating cancers. CN101683331; 2010
47. Li SS, Zhou W, Wang RB, et al. Water-soluble alkylated shikonin naphthazarin nucleus derivatives useful in the treatment leukemia and their preparation. CN101863786; 2010
48. Park JH, Kim SY, Kang TH, et al. Pharmaceutical composition comprising shikonin derivatives from Lithospermum erythrorhizon for treating or preventing diabetes mellitus. WO200807279; 2009
49. Singh B, Sharma MK, Meghwal PR, et al. Anti-inflammatory activity of shikonin derivatives from arnebia hispidissima. Phytomedicine 2003;10:375-80 (Pubitemid 36745159)
50. Wang F. Application of shikonin and its derivative in medicine. WO2004073699; 2004
51. Kourounakis AP, Assimopoulou AN, Papageorgiou VP, et al. Alkannin and shikonin: Effect on free radical processes and on inflammation-a preliminary pharmacochemical investigation. Arch Pharm 2002;335:262-6 (Pubitemid 34951600)
52. Lu L, Qin A, Huang H, et al. Shikonin extracted from medicinal chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol 2011;658:242-7. That proteasome inhibition by shikonin contributes to its anti-inflammatory effect was demonstrated for the first time.
53. Karayannopoulou M, Loukopoulos P, Papazogiou LG, et al. Naturally occurring isohexenylnaphthazarins and wound healing: Experimental study in dogs. J Cutan Med Surg 2010;14:62-70
54. Karayannopoulou M, Tsioli V, Loukopoulos P, et al. Evaluation of the effectiveness of an ointment based on alkannins/shikonins on second intention wound healing in the dog. Can J Vet Res 2011;75:42-8
55. Wu Z, Wu LJ, Li L, et al. P53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 2004;94:166-76 (Pubitemid 38405131)
56. Liu J, ZhouW, Li SS, et al. Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues. Cancer res 2008;68:8871-80
57. Kim SH, Kang IC, Yoon TJ, et al. Antitumor activities of a newly synthesized shikonin derivative, 2-hyim- DMNQ-S-33. Cancer lett 2001;172:171-5 (Pubitemid 32889713)
58. Singh F, Gao D, Lebwohl MG, et al. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer lett 2003;200:115-21 (Pubitemid 38366091)
59. Chang IC, Huang YJ, Chiang TI, et al. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells. Biol Pharm Bull 2010;33:816-24
60. Wang WJ, Dai M, Zhu CH, et al. Synthesis and biological activity of novel shikonin analogues. Bioorg Med Chem Lett 2009;19:735-7. The significant biological activities of shikonin and its analogues relating to HIF-1 pathway was reported firstly.
61. Lee H J, Lee H-J, Song Y, et al. 6 - (1 - Oxobutyl) - 5, 8 - dimethoxy - 1, 4 - naphthoquinone inhibits lewis lung cancer by antiangiogenesis and apoptosis. Int J cancer 2007;120:2481-90 (Pubitemid 46642138)
62. Liu X, Niu X, Zhou W, et al. Growth inhibitory effect of beta-hydroxyisovalerylshikoninon prostate cancer cells and related mechanism. J Shanghai Jiaotong Univ (Medical Science) 2010;30:527-30
63. Masuda Y, Shima G, Aiuchi T, et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem 2004;279:42503-15 (Pubitemid 39372134)
64. Mao X, Yu CR, Li WH, et al. Cell research: Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 2008;18:879-88
65. Hsu PC, Huang YT, Tsai ML, et al. Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem 2004;52:6330-7
66. Cheng HM, Qiu YK, Wu Z, et al. DNA damage induced by shikonin in the presence of Cu (II) ions: Potential mechanism of its activity to apoptotic cell death. J Asian Nat Prod Res 2011;13:12-19
67. Ruan M, Yan M, Yang WJ, et al. Role of NF-kappaB pathway in shikonin induced apoptosis in oral squamous cell carcinoma Tca-8113 cells. Shanghai kou qiang yi xue 2010;19:66-71
68. Nakaya K, Kajimoto Y, Hsu M, et al. Shikonin derivatives as tyrosine kinase inhibitors and antitumor agents. JP2002212065; 2002
69. Takai N, Ueda T, Nishida M, et al. beta-Hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol 2008;109:107-14
70. Masuda Y, Nishida A, Hori K, et al. beta-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 2003;22:1012-23 (Pubitemid 36313145)
71. Yang HJ, Zhou P, Huang HB, et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 2009;124:2450-9
72. Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007;6:1641-9 (Pubitemid 46954031)
73. Xuan YY, Hu X. Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett 2009;274:233-42
74. Chen J, Xie J, Jiang Z, et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011;30:4297-306. Shikonin and alkannin are the most potent and specific inhibitors to PKM2 reported so far.
75. Lee HJ, Magesh V, Nam D, et al. Shikonin, acetylshikonin, and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice. Yakugaku Zasshi 2008;128:1681-8
76. Min R, Zun Z, Min Y, et al. Shikonin inhibits tumor invasion via down-regulation of NF-kappaB-mediated MMP-9 expression in human ACC-M cells. Oral Dis 2011;17:362-9
77. Chen X, Yang L, Zhang N, et al. Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003;47:2810-16 (Pubitemid 37040252)
78. Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin cancer res 2009;15:1126-32
79. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12 (Pubitemid 28406816)
80. Yoo Y, Kim YO, Lim NY, et al. Shikonin, an ingredient of lithospermum erythrorhizon induced apoptosis in hl60 human premyelocytic leukemia cell line. Planta Med 1999;65:532-5
81. Hsu PC, Huang TY, Tsai ML, et al. Induction of apoptosis by shikonin through coordinative modulation of the bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem 2004;52:6330-7
82. Gao D, Hiromura M, Yasui H, et al. Direct reaction between shikonin and thiols induces apoptosis in hl60 cells. Biol Pharm Bull 2002;25:827-32 (Pubitemid 40022107)
83. Hou Y, Guo T, Wu C, et al. Effect of shikonin on human breast cancer cells proliferation and apoptosis in vitro. Yakugaku Zasshi 2006;126:1383-6 (Pubitemid 46089900)
84. Yen CC, Kuo HM, Li TM, et al. Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line. In Vivo 2007;21:1011-20
85. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Gene Dev 2002;12:60-6 (Pubitemid 34094991)
86. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997;326:1-16 (Pubitemid 27386911)
87. Adam JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-6 (Pubitemid 28406819)
88. Yang J, Liu XS, Bhalla K, et al. Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997;275:1129-32 (Pubitemid 27097312)
89. Yinxm XM, Oltwvi ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3 (Pubitemid 24159542)
90. Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: A control point for apoptosis. Science 2003;300:135-9 (Pubitemid 36423046)
91. Thompson J, Winoto A. During negative selection, Nur77 family proteins translocate to motochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. J Exp Med 2008;205:1029-36 (Pubitemid 351679679)
92. Johnson GL, Lapadat R.Mitogen-activated protein kinase pathways mediated by erk, jnk, and p38 protein kinases. Science 2002;298:1911-12 (Pubitemid 35425238)
93. Seger R, Krebs EG. The MAPK signaling cascade. Faseb J 1995;9:726-35
94. Roberts CJ, Nelson B, Marton MJ. Signaling and circuitry of multiple mapk pathways revealed by a matrix of global gene expression profiles. Science 2000;287:873-80 (Pubitemid 30084333)
95. Rao Z, Liu X, Zhou W, et al. Synthesis and antitumor activity of beta-hydroxyisovalerylshikonin analogues. Eur J Med Chem 2011;46:3934-41
96. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25 (Pubitemid 26193625)
97. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12
98. Ottenhoff-kalff AE, Rijksen G, Van Beurden EACM, et al. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 1992;52:4773-8
99. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: The metabolic requirements of cell proliferation. Science 2009;324:1029-33
100. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006;312:594-607 (Pubitemid 43290336)
101. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4 (Pubitemid 129519680)
102. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74 (Pubitemid 37328786)